FDA Approves Basaglar® (insulin glargine injection), a Long-Acting Insulin Treatment

• BASAGLAR is the first FDA-approved follow-on insulin glargine treatment • BASAGLAR will be available in the U.S. starting on December 15, 2016

Source: Boehringer Ingelheim Press Releases - December 15, 2015 Category: Research Source Type: news